Biomea Fusion’s early-stage investigational diabetes treatment BMF-291 has been slapped with a full FDA clinical hold on its ...

After rejecting a previous takeover offer from Future Pak, Vanda Pharmaceuticals is now fielding another acquisition proposal ...

AbbVie’s antibody-drug conjugate Elahere, developed by ImmunoGen, elicited a nearly 52% objective response rate in heavily ...

Both Eli Lilly and the partnered companies Boehringer Ingelheim and Zealand Pharma have mid-stage data readouts this week, ...

BWXT Medical Ltd. has submitted a Drug Master File to the U.S. Drug and Food Administration for No Carrier Added Actinium-225 Active Pharmaceutical Ingredient.

UroGen Pharma Ltd. today announced the grants of inducement restricted stock units (“RSUs”) and an option (“Option”) to 15 new employees in connection with their employment with UroGen. BWXT Medical ...

Single Pass and Mermaid Medical have confirmed that four patients were successfully treated with the Kronos Biopsy Closure device at MemorialCare Long Beach Medical Center. Equillium Inc. today ...

BMS presented late-stage results on Tuesday at the ASCO annual meeting which showed the combination of Opdivo and Yervoy ...

In a briefing document ahead of Monday’s FDA advisory committee meeting, the agency’s internal reviewers have raised several ...

Boehringer Ingelheim and Zealand Pharma on Friday unveiled Phase II findings for their investigational GLP-1/glucagon ...

Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis ...

Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. successfully completed the Phase I clinical trial of its self-developed new injectable polymyxin antibacterial drug MRX-8 in China, achieving the ...